Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220616) titled 'A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies' on Oct. 21.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Daiichi Sankyo
Condition:
Hematological Malignancies
Intervention:
Drug: DS3790a
Drug: Combination drug
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: November 15, 2025
Target Sample Size: 420
To know more, visit https://clinicaltrials.gov/study/NCT07220616
Published by HT Digital Content Servic...